Unknown OBSERVATIONAL NCT04358627

Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients (COVID-DEX)

Impact of Dexmedetomidine Infusion on the Time Course and Outcomes of Acute Respiratory Distress Syndrome (ARDS) in Patients Affected by the SARS-CoV-2 (COVID-19) Admitted to Critical Care Unit

Sponsor: Hospital Clinic of Barcelona

Conditions Acute Respiratory Distress Syndrome Cytokine Storm Delirium, Emergence Dexmedetomidine Inflammation

Interventions Dexmedetomidine Injectable Product

Updated 5 times since 2020 Last updated: Apr 22, 2020 Started: Apr 15, 2020 Primary completion: May 30, 2020 Completion: Jun 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04358627, this observational or N/A phase trial focuses on Acute Respiratory Distress Syndrome and Cytokine Storm and remains ongoing. Sponsored by Hospital Clinic of Barcelona, it has been updated 5 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
May 2022 — Jul 2024 [monthly]

Unknown Status

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — May 2022 [monthly]

Not Yet Recruiting
May 2020 — Jan 2021 [monthly]

Not Yet Recruiting

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Clinic of Barcelona

Data source: Hospital Clinic of Barcelona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.